Literature DB >> 31580445

Rituximab in minimal change disease and focal segmental glomerulosclerosis.

Andreas Kronbichler1, Philipp Gauckler1, Annette Bruchfeld2.   

Abstract

Entities:  

Year:  2021        PMID： 31580445     DOI： 10.1093/ndt/gfz205

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  3 in total

Review 1.  CD80 Insights as Therapeutic Target in the Current and Future Treatment Options of Frequent-Relapse Minimal Change Disease.

Authors:  Yoong Mond Teh; Soo Kun Lim; Norhana Jusoh; Kahar Osman; Siti Aisyah Mualif
Journal:  Biomed Res Int       Date:  2021-01-06       Impact factor: 3.411

2.  PD-1 and PD-L1 Expression on Circulating Lymphocytes as a Marker of Epstein-Barr Virus Reactivation-Associated Proliferative Glomerulonephritis.

Authors:  Ewelina Grywalska; Iwona Smarz-Widelska; Izabela Korona-Głowniak; Sebastian Mertowski; Krzysztof Gosik; Anna Hymos; Jarosław Ludian; Paulina Niedźwiedzka-Rystwej; Jacek Roliński; Wojciech Załuska
Journal:  Int J Mol Sci       Date:  2020-10-27       Impact factor: 5.923

3.  Rituximab Induces Complete Remission of Proteinuria in a Patient With Minimal Change Disease and No Detectable B Cells.

Authors:  Maximilian Webendörfer; Linda Reinhard; Rolf A K Stahl; Thorsten Wiech; Hans-Willi Mittrücker; Sigrid Harendza; Elion Hoxha
Journal:  Front Immunol       Date:  2021-02-08       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.